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Background: The clinical importance of preoperative tumor markers remain elusive in gastric cancer. The aim of
this study was to evaluate the prognostic value of AFP, CEA, CA19-9, and CA50 in T4a stage gastric cancer.
Methods: Two hundred and seventy-three T4a gastric cancer patients who underwent curative D2 gastrectomy
between 1996 and 2005 were evaluated. The correlation between tumor markers and clinicopathologic
characteristics and prognostic value of preoperative tumor markers were investigated.
Results: Correlation analysis showed that AFP was associated with Borrmann type (P= 0.010); CEA with sex
(P= 0.029), tumors site (P= 0.014), and N stage (P= 0.001); CA19-9 with age (P= 0.047), tumor site (P= 0.011),
lymphovascular invasion (P= 0.004), and N stage (P= 0.000); CA50 with age (P= 0.017), tumor site (P= 0.004), tumor
size (P= 0.014), and N stage (P= 0.000). Multivariate analysis showed that the positivity of preoperative CEA, CA19-9,
and CA50 were major independent poor prognostic factors of patients with T4a stage gastric cancer.
Conclusions: Preoperative serum tumor marker might be a candidate for the staging system in addition to
conventional factors.
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Gastric cancer was the fourth common cancer world-
wide, and it was the second most common cause of
death from cancer [1]. Although the survival of gastric
cancer had been improved dramatically in some coun-
tries, especially in Japan, possibly due to early diagnosis
following a great number of endoscopic examinations
performed for gastric disorders, survival was still rela-
tively low in North America and Western Europe even
in cases treated by radical surgery, which raised the
question whether the molecular pathology of gastric
cancer was similar worldwide [2-4]. Therefore, a major
impetus for the current study was the lack of previous
studies on a large-scale Chinese population evaluating
the expression of molecular prognostic markers in gas-
tric cancer patients. Because of the variability of prog-
nosis within a clinical or pathological stage of gastric
cancer at presentation, which showed tumor stage* Correspondence: wangyn1111@hotmail.com
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reproduction in any medium, provided the orcould not provide complete information on the clinical
behavior of gastric cancer, there has been a constant
search for specific biological markers to identify sub-
groups of patients with more aggressive course of dis-
ease [5-7]. Some serum tumor markers including alpha-
fetoprotein (AFP), carcinoembryonic antigen (CEA),
carbohydrate antigen (CA) 19-9, CA50, and CA72-4
have been reported to be elevated in some patients with
gastric cancer [8-10]. AFP, discovered about half a cen-
tury ago by Abelev et al., was a sensitive marker for
diagnosis of hepatocellular cancer [11]. The serum level
of AFP also increased in AFP-producing gastric cancer
[12,13]. CEA, originally described in 1965 by Gold and
Freedman, was routinely used as a serum marker for
colorectal cancer [14]. CEA was a glycoprotein from the
family of immunoglobulins whose function was to pro-
mote cellular binding. CA19-9, first described by
Koprowski et al. in 1979 as a marker for colorectal can-
cer, had become the most important tumor marker for
pancreatic adenocarcinoma [15]. CA19-9 was a high-
molecular weight mucin that played a role in the adhe-
sion of cancer cells to endothelial cells. CA50, initially
screened out of colorectal cancer cell lines by HolmgrenThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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played an important part in growth and differentiation
of cell [16]. CA72-4 was a complex glycoprotein that
elevated in the serum of patients’ breast, pancreatic, ovar-
ian, colon, and gastric cancers. CA72-4 was regarded as
one of the most specific and sensitive markers for gastric
cancers. However, it has not been routinely tested for gas-
tric cancer patients in our hospital before 2005. At the
present time, the value of these tumor markers in T4a stage
gastric cancer was still elusive, which was responsible for
more than 40% of gastric cancer and likely to present ab-
normal serum level of tumor markers. In this retrospective
study, we evaluated the association between tumor markers
and clinicopathological features and the prognostic value of
tumor markers in T4a stage gastric cancer.
Methods
Patients
In total, 273 patients with histologically confirmed pri-
mary gastric adenocarcinoma underwent curative gas-
trectomy at the Department of Abdominal Surgery,
Cancer Hospital, Fudan University between January 1996
and December 2005. Data were retrieved from their op-
erative and pathological reports, and follow-up data were
obtained by phone, outpatient clinical database, and let-
ter. Informed consent was given to all participants. Eth-
ical approval was given by Cancer Hospital. The study
comprised 192 men and 81 women aged 22 to 78 years,
mean age was 56 ± 12 years. There were 117 patients
aged more than 59 years; the ratio of men to women was
192:81; 14 patients had a family history of gastric cancer;
198 patients liked to eat fried food, 50 patients liked to
eat food rich in fat, and the other 25 patients had no spe-
cial preference to fried food or fatty food; 64 cases had a
history of smoking. Staging was performed according to
the American Joint Committee on Cancer (AJCC) TNM
Staging Classification for Carcinoma of the Stomach
(Seventh Edition, 2010) [17]. All the patients belonged to
T4a gastric cancer according to the AJCC/TNM Staging
System. Gastrectomy was performed in accordance with
the Japanese Classification of Gastric Carcinoma [18].
D2 gastrectomy, complete dissection of the first-tier
and second-tier lymph nodes, was performed in all 273
patients. In each case, 15 or more lymph nodes were
dissected according to the AJCC/TNM classification. A
follow-up of all patients was carried out according to
our standard protocol (every 3 months for at least
2 years, every 6 months for the next 3 years, and after
5 years every 12 months for life). The check-up items
included physical examination, tumor-marker examin-
ation, ultrasound, chest radiography, computed tomo-
graphic scan, and endoscopic examination. The median
follow-up time was 61.2 months for patients still alive
at the time of analysis.Serum assays for AFP, CEA, CA19-9, and CA50
Blood samples were obtained from all patients in the
morning during the week before surgery. The blood sam-
ple was centrifuged at 1000 g for 10 min to separate the
plasma from the blood cells. AFP, CEA, CA19-9, and
CA50 were assayed with magnetic particle enzyme im-
munoassay in UniCelTM DxI 800 Access immunoassay
system (Beckman Coulter Inc. Miami of U.S.A). The cut-
off value for serum AFP, CEA, CA19-9, and CA50 were
10 μg/L, 10 μg/L, 37 U/mL, and 20 U/mL, respectively,
according to the manufacturer’s instructions.
Adjuvant chemotherapy
A total of 223 patients received adjuvant chemotherapy
within 4 weeks after surgery. There were four kinds of
chemotherapy regimens in our study: (1) oral administra-
tion of tegafur 600 mg per day for at least 1 year (n= 80);
(2) oral administration of doxifluridine 1200 mg per day
for at least 1 year (=65); (3) a combination of 5-fluorour-
acil, cisplatin, and mitomycin C, 500 mg/m2 5-fluoroura-
cil was administrated by intravenous infusion from days
1 to 5, 20 mg/m2 cisplatin intravenous from days 1 to 5,
and 8 mg mitomycin C intravenous on day 1, then
repeated every 21 days for at least six cycles (n= 43); and
(4) combination of 5-fluorouracil and hydroxycamp-
tothecine, intravenous administration of 500 mg/m2 5-
fluorouracil, and 8 mg/m2 hydroxycamptothecine from
days 1 to 5, repeated every 21 days for at least six cycles
(n= 43).
Statistical methods
The association between tumor markers and clinico-
pathological factors was evaluated by Chi-square test.
The 5-year survival rates were calculated by Kaplan-
Meier method [19], and differences between survival
curves were examined with log-rank test. The independent
prognostic value of tumor markers and clinicopathological
features was analyzed by Cox proportional hazards
model [20]. Differences were considered statistically sig-
nificant when the P value was< 0.05. Statistical analysis




Of the 273 reviewed patients, 90 patients had tumors
located in the upper third of the stomach, 52 patients
had tumors in the middle third, 124 patients had tumors
in the lower third, and seven patients had tumors occu-
pying two-thirds of the stomach or more. The distribu-
tion of postoperatively pathological stages of the patients
was as follows: 49 patients belonged to IIB stage, 49
patients to IIIA stage, 52 patients to IIIB stage, and 123
patients to IIIC stage. Partial gastrectomy was performed
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80 patients.Positive rates of tumor markers
The preoperative serum positive rates of AFP, CEA,
CA19-9, and CA50 were 5.9%, 16.1%, 32.6% and 29.7%,
respectively. The serum value of AFP ranged from 0 to
3000 μg/L (mean 17.26 μg/L, and median 1.85 μg/L),
CEA from 0 to 401 μg/L (mean 15.84 μg/L, and median
1.67 μg/L), CA19-9 from 1 to 1000 U/mL (mean 68.81 U/
mL, and median 15.58 U/mL), CA50 from 0 to 549 U/mL
(mean 37.02 U/mL, and median 12.00 U/mL).Correlation analysis
Patients with positive CEA, CA19-9, or CA50 showed a
more advanced tumor stage than those with negative
values (P =0.001, 0.000, and 0.000, respectively). Presence
of occupying two-third of stomach or more was more
frequent in those patients with positive CEA, CA19-9, or
CA50 (P =0.014, 0.011, 0.004, respectively). The propor-
tions of young patients were significantly higher in those
with elevated serum CA19-9 (P= 0.047) and CA50
(P= 0.017) levels than those with normal levels. A statis-
tically significant positive rate was found for CEA (P
=0.029) level in males. Borrmann IV was more frequent
in those with positive AFP (P =0.010). The patients with
lymphovascular invasion more frequently showed higher
values of CA19-9 (P =0.004). Patients with large-sized
tumors were associated with significantly high positive
rates of CA50 (P =0.014). The status of nervous invasion
did not influence the positivity of the tumor markers
(Table 1).Univariate analysis
The over-all 5-year survival rate was 38.1% for all 273
patients. The significant prognostic factors included: the
serum level of AFP, CEA, CA19-9, and CA50 (Figure 1),
age, tumor size, tumor site, Borrmann type, lymph node
stage, nervous invasion, and lymphovascular invasion
(Table 2). The 5-year survival was lower in patients with
elevated AFP (P =0.012), CEA (P =0.000), CA19-9 (P
=0.000), or CA50 (P =0.000) compared with those
patients with normal levels of tumor markers. The 5-year
survival was longer in patients with pN0 or pN1 than
patients with pN2 or pN3 (P =0.000), in older patients
(P =0.038), in patients with small size tumor (P =0.003),
in patients with a presence occupying less than two-
thirds of the stomach (P =0.008), in patients without
Borrmann IV (P =0.017), in patients without nervous inva-
sion (P =0.000) or lymphovascular invasion (P =0.000).
The sex, adjuvant chemotherapy did not show any rela-
tionship with survival.Multivariate analysis
Multivariate survival analysis was performed by evaluating
all significant prognostic factors from univariate analysis
to determine the independent prognostic factors for T4a
stage gastric cancer. Multivariate analysis using Cox pro-
portional hazards model showed that tumor markers, in-
cluding CEA, CA19-9, and CA50, were independent
prognostic factors, as tumor size, lymph node stage, and
nervous invasion. According to the relative risk, these
independent prognostic factors were ranked as CEA,
CA19-9, nervous invasion, CA50, pN stage, and tumor
size by descending (Table 3).
Comparison of survival according to CEA, CA19-9, and
CA50
According to AJCC/TNM Staging System, T4a stage gas-
tric cancer was divided into four stages: IIB, IIIA, IIIB,
and IIIC. Based on CEA, CA19-9, and CA50, which are
all independent prognostic factors, stages II and III were
divided into CEA (+) and CEA (-), CA19-9 (+) and
CA19-9 (-), CA50 (+) and CA50 (-), respectively. There
were significant differences of overall 5-year survival be-
tween CEA (+) and CEA (-) according to stage II and III
(P =0.002 and 0.000, respectively; Figure 2). There were
significant differences of overall 5-year survival be-
tween CA19-9 (+) and CA19-9 (-) according to stage III
(P =0.000; Figure 3). There were significant differences of
overall 5-year survival between CA50 (+) and CA50 (-)
according to stage III (P =0.000; Figure 4).
Discussion
The main findings of this study were: (1) tumor markers
including CEA, CA19-9, and CA50 were independent
prognostic factors for T4a stage gastric cancer; and (2)
there were significant differences of overall 5-year sur-
vival rate between CEA (+) and CEA (-) according to
stages II and III; between CA19-9 (+) and CA19-9 (-)
according to stage III; between CA50 (+) and CA50 (-)
according to stage III.
Various tumor markers have been identified since Gold
and Freedman first reported the discovery of carcinoem-
bryonic antigen (CEA) in 1965 [14]. These tumor mar-
kers have been studied primarily for applicability and
feasibility in terms of tumor early detection. Among
these tumors, AFP, CEA, CA19-9, CA50, and CA72-4
were considered as relatively specific markers for gastric
cancers. In particular, CA 72-4 was regarded as one of
the most specific and sensitive markers for gastric can-
cers. However, as a retrospective study, we could only
evaluate the prognostic value of AFP, CEA, CA19-9, and
CA50 for gastric cancers, which were evaluated in our
institute. A few of studies have investigated the value of
various tumor markers, including CEA, CA19-9, and
CA50 in gastric cancer [21-23]. Some reports showed










Sex 0.408 0.029 0.213 0.242
Male (192) 13 (6.8) 37 (19.3) 67 (34.9) 61 (31.8)
Female (81) 3 (3.7) 7 (8.6) 22 (27.2) 20 (24.7)
Age (years) 0.053 0.779 0.047 0.017
≤40 (26) 4 (15.4) 3 (11.5) 13 (50.0) 13 (50.0)
>40 (247) 12 (4.9) 41 (16.6) 76 (30.8) 68 (27.5)
Tumor site 0.153 0.014 0.011 0.004
Upper (90) 5 (5.6) 16 (17.8) 31 (34.4) 31 (34.4)
Middle (52) 3 (5.8) 5 (9.6) 19 (36.5) 15 (28.9)
Lower (124) 6 (4.8) 19 (15.3) 33 (26.6) 29 (23.4)
≥Two-third (7) 2 (28.6) 4 (57.1) 6 (85.7) 6 (85.7)
Tumor size 0.063 0.812 0.102 0.014
≤6 (178) 7 (3.9) 28 (15.7) 52 (29.2) 44 (24.7)
>6 (95) 9 (9.5) 16 (16.8) 37 (38.9) 37 (38.9)
Borrmann type 0.010 0.365 0.086 0.066
I (15) 0 (0.0) 2 (13.3) 4 (26.7) 3 (20.0)
II (8) 1 (12.5) 0 (0.0) 4 (50.0) 2 (25.0)
III (228) 10 (4.4) 36 (15.8) 69 (30.3) 64 (28.1)
IV (22) 5 (22.7) 6 (27.3) 12 (54.6) 12 (54.6)
N stage 0.065 0.001 0.000 0.000
N0 (49) 0 (0.0) 3 (6.1) 7 (14.3) 6 (12.2)
N1 (49) 1 (2.0) 6 (12.2) 14 (28.6) 14 (28.6)
N2 (52) 4 (7.7) 3 (5.8) 10 (19.2) 9 (17.3)
N3 (123) 11 (8.9) 32 (26.0) 58 (47.2) 52 (42.3)
Nervous invasion 0.156 0.520 0.051 0.294
+ (197) 9 (4.6) 30 (15.2) 71 (36.0) 62
(31.5)
- (76) 7 (9.2) 14 (18.4) 18 (23.7) 19 (25.0)
Lymphovascular invasion 0.399 0.212 0.004 0.085
+ (196) 10 (5.1) 35 (17.9) 74 (37.8) 63
(32.7)
- (77) 6 (7.8) 9 (11.7) 15 (19.5) 17 (22.1)
Figures shown in parentheses are percentages.
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clinical outcomes such as prognosis, response to treat-
ment, and recurrence, although results were not consist-
ent. Furthermore, these studies have been counteracted
by several methodologic flaws: (1) the inclusion of
patients with various tumor stages raging from localized
to metastatic; and (2) a heterogeneous treatment regi-
men. So it is necessary to clarify the value of tumor mar-
kers in homogeneous group of patients with gastric
cancer.
We only evaluated patients with T4a N0-3 M0 gastric
cancer, who received D2 gastrectomy. The reasons for
including only T4a gastric cancers as follows: (1) Therehave been some studies on the prognostic impact of
tumor markers in gastric cancer, but rarely have the pre-
vious studies evaluated the prognostic impact of tumor
markers when specific depth of invasion was involved,
especially in the T4a classification which was responsible
for more than 40% of gastric cancers. Therefore, the pre-
cise determination of the prognostic value of tumor mar-
kers in T4a gastric cancer has substantial clinical
importance. (2) Since some previous studies showed an
association between the depth of tumor invasion and
serum tumor markers levels [24,25], it was difficult to
identify the important prognostic factors as a result of
interrelated factors. In each case, 15 or more lymph
Figure 1 Comparison of cumulative curves according to AFP level, CEA level, CA19-9 level, and CA50 level. Patients with elevated serum
AFP, CEA, CA19-9, or CA50 levels had a significantly worse prognosis than patients with normal levels of either marker (P =0.012, 0.000, 0.000, and
0.000, respectively).
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cation. In this study, the positive rate of patients with
elevated serum AFP levels was 5.9%, which was similar
to those reported by other investigators [12,24,26]. The
positive rate of CEA and CA19-9 were 16.1% and 32.6%,
respectively, which are lower than that of other studies
[27,28]. The corresponding proportion of patients with
elevated serum CA50 levels was 29.7%. The positive rates
of tumor markers are thought to be influenced by tumor
progression at the time of presentation. When the serum
positive rates of AFP, CEA, CA19-9, and CA50 were
evaluated according to TNM stage grouping, it showed
that the positive rates increased gradually with stage.
We compared other clinicopathological factors between
patients with elevated tumor markers and those with nor-
mal levels of serum tumor markers. The proportion of
patients with elevated serum AFP was significantly higherin those with Bormmann IV. The elevated serum CEA was
associated with gender, tumor site, and pN stage. The ele-
vated serum CA19-9 was associated with age, tumor site,
lymphovascular invasion, and pN stage. CA50 positivity
was significantly associated with age, tumor size, tumor
site, and pN stage. We found that these tumor markers
were associated with pN stage. This finding indicated that
the positive rates of tumor markers increased as the tumor
progressed. This was agreement with previous studies of
AFP, CEA, and CA19-9 [25,26]. Additionally, we found
that the positive rate of CEA was higher in males than in
females, which was not consistent with previous some
studies [26,29]. It was possible that the limited samples in
these studies contributed to the negative correlation be-
tween CEA and gender. This result indicated that the
serum CEA should be investigated in patients with gastric
cancer, especially for male patients.
Table 3 Independent prognostic factors at multivariate
analysis by Cox Model
Factors Hazard ratio 95% CI P
CEA 2.809 1.823–4.327 0.000
CA19-9 2.740 1.620–4.635 0.000
CA50 2.091 1.236–3.538 0.006
Tumor size 1.595 1.147–2.219 0.006
pN stage 1.624 1.378–1.914 0.000
Nervous invasion 2.510 1.456–4.325 0.001
Table 2 Predictors of overall survival according to the
univariate analysis
















Age (years) 4.300 0.038
≤40 (26) 23.1
>40 (247) 39.7





Tumor size 8.687 0.003
≤6 (178) 42.7
>6 (95) 29.5










Nervous invasion 17.848 0.000
+ (197) 29.9
-(76) 59.2
Lymphovascular invasion 17.242 0.000
+ (196) 30.6
-(77) 57.1
Adjuvant chemotherapy 1.443 0.230
Yes (223) 39.0
No (50) 34.0
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that there was a significant difference in 5-year overall
survival in terms of tumor markers and distinct clinico-
pathologic factors, which included age, tumor size,
tumor site, Borrmann type, lymph node stage, nervous
invasion, and lymphovascular invasion. We found that
the serum levels of AFP, CEA, CA19-9, and CA50 were
significantly correlated with survival rate in patients
with T4a stage gastric cancer, which was in agreement
with previous studies of AFP, CEA, and CA19-9
[25,26,29]. These correlations indicated that patients
with positive values of tumor markers have worse prog-
nosis, which in turn may be due to the predominant
proportion of advanced gastric cancer in this cohort of
patients.
Multivariate analysis using Cox proportional hazards
model showed that tumor markers including CEA,
CA19-9, CA50, were independent prognostic factors,
as tumor size, lymph node stage, and nervous inva-
sion. The Cox proportional hazards regression analysis
showed that patients with elevated levels of CEA,
CA19-9, and CA50 had a higher risk of death than
patients with low levels of these markers. Except
CA50, the prognostic value of CEA and CA19-9 in
gastric cancer had been widely studied. Tocchi et al.
[30] found that CEA and CA19-9 provided independ-
ent predictive value in gastric cancer patients, but the
other studies did not show consistent result [26,29].
This was likely due to the heterogeneity of patients
included in these studies, including those with loca-
lized disease who undergo gastrectomy and those with
locally advanced and disseminated disease who may
not undergo resection.
To evaluate whether serum CEA, CA19-9, and CA50
could provide additional prognostic information on the
basis of AJCC/TNM stage system, we compared cumula-
tive survival curves according to CEA, CA19-9, and
CA50. The results showed that there were significant dif-
ferences between patients with elevated levels and those
with normal serum CEA, CA19-9, and CA50 levels at
stage III. These findings indicated that serum CEA,
CA19-9, and CA50 levels could provide additional
Figure 2 Comparison of survival according to stages II and III. A significant difference in survival of patients with stages II and III was
observed between positive CEA and negative CEA (P =0.002 and 0.000, respectively).
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stage gastric cancer. Similar results in patients with gas-
tric cancer have been reported by others. A previous
study reported that the survival rate of gastric cancerFigure 3 Comparison of survival according to stages II and III. A signif
between positive CA19-9 and negative CA19-9 (P= 0.000).patients at stages I, II, and III with elevated serum CEA
levels was significantly poorer than that of patients with
normal levels [31]. Another study reported that there
were significant differences between patients withicant difference in survival of patients with stage III was observed
Figure 4 Comparison of survival according to stages II and III. A significant difference in survival of patients with stage III was observed
between positive CA50 and negative CA50 (P =0.000).
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stage I [23]. The reason that preoperative levels of tumor
markers could influence long-survival of T4a gastric can-
cer was still unclear; it was possible that a number of
biological factors are involved. CEA and CA19-9
belonged to intercellular adhesion molecules, so cells
expressing these glycoproteins may have a greater inva-
sive potential [8]. CA50 acted as a kind of glycolipid
antigen that played a role in growth and differentiation
of cell, suggesting that cells expressing this antigen
would possess increased proliferating activity [16].
Some limitations of this study should be acknowl-
edged. Firstly, we only evaluated patients with T4a N0-
3 M0 gastric cancer. Although this is a design of the
study, only inclusion of T4a stage gastric cancers would
limit the application of the results to the early stage or
more unfavorable moderate stage gastric cancer. Sec-
ondly, CA72-4 was not routinely tested for gastric cancer
before 2005 in our hospital, therefore its predicting value
for gastric cancer was not known. Thirdly, as a result of
uncompleted data about recurrence, it was unable to
evaluate the correlation between tumor markers and re-
currence. Fourthly, we could not determine the prognos-
tic value of peritoneal cytology in our study, because we
did not perform peritoneal cytology in the management
of gastric cancer. Therefore, this may have influenced
the survival data. In addition, some other molecularmarkers such as cell-free DNA (cfDNA) and miRNA
should be investigated in future. Previous studies have
demonstrated an increase of circulating cfDNA in differ-
ent types of cancer [32]. MicroRNA (miRNA) played an
important role in regulating gene express. Chen et al.
[33] found that expression pattern of serum miRNA was
altered in reflection of various disease.Conclusions
In conclusion, tumor marker, which can be easily mea-
sured before surgery, is a simple and reliable prognostic
factor in T4a stage gastric cancer. Therefore it might be
a candidate for the staging system in addition to conven-
tional factors. However, as a retrospective study, our data
could not allow us to directly address some issues.
Large-scale, prospective studies, which combined tumor
markers and molecular markers like cfDNA and miRNA,
are needed to answer above mentioned questions in
future.Competing interests
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